Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to ...

Today, the big excitement around the business is due to its GLP-1 drugs, Zepbound and Mounjaro, with the former approved for weight loss and the ... to buy and hold. Big-box retailer Walmart ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version ... As we talk, she marvels that she's had a box of ...

There is also an FDA box warning for thyroid C-cell tumors ... but the drug does not have FDA approval for this use. Zepbound is an injectable weight-loss drug for people who have obesity or ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound ... she marvels that she's had a box of chocolates on her desk all day ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come ... of the increasingly competitive weight-loss drug market, telling CNBC in ...

In FQ4 2024, the company’s weight-loss drug sales fell short, with Mounjaro revenue at $3.5 billion (vs. the $5.35 billion estimate) and Zepbound at $1.9 billion (vs. the $2.08 billion estimate).

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...